Literature DB >> 32580954

Mild or Malign: Clinical Characteristics and Outcomes of Clostridium difficile Infection in Thailand.

Korakrit Imwattana1,2, Papanin Putsathit3, Teera Leepattarakit2, Pattarachai Kiratisin2, Thomas V Riley4,3,5,6.   

Abstract

Little is known about the clinical characteristics of Clostridium difficile infection (CDI) in Asia in general, and Thailand specifically, with a few studies suggesting that the disease may be milder than elsewhere. This study aimed to describe CDI in Thailand, evaluate treatment options and their outcomes, and explore possible protective factors responsible for any unique disease characteristics. From 2015 to 2018, 469 patients were included in the study. All patients had their stools tested for the tcdB gene by direct PCR and detection of toxigenic C. difficile by culture. C. difficile isolates were subjected to toxin gene profiling and ribotyping, and patient medical records were reviewed retrospectively. There were 248 and 221 patients included in CDI and control groups, respectively. The CDI group had a higher overall 30-day mortality rate than the control group (21% versus 14%, P = 0.046), but only 2 deaths (1%) were directly attributable to CDI. Metronidazole treatment was not inferior to vancomycin in this population, and vancomycin was associated with a higher 30-day mortality rate (P = 0.047). The prevalence of severe CDI and disease outcomes were not different between patients infected with A-B+ C. difficile and A+B+ C. difficile strains or between patients with and without colonization by nontoxigenic C. difficile Besides C. difficile-specific tests, neither a single laboratory result nor a combination of results was predictive of CDI. In conclusion, CDI in Thailand was relatively mild, and metronidazole remained an effective treatment option for these mild infections.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Clostridium difficile infection; Thailand; clinical characteristics

Mesh:

Substances:

Year:  2020        PMID: 32580954      PMCID: PMC7448632          DOI: 10.1128/JCM.01217-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

Authors:  Hude Quan; Bing Li; Chantal M Couris; Kiyohide Fushimi; Patrick Graham; Phil Hider; Jean-Marie Januel; Vijaya Sundararajan
Journal:  Am J Epidemiol       Date:  2011-02-17       Impact factor: 4.897

2.  EPIDEMIOLOGY AND CONTROL OF THE FIRST REPORTED VANCOMYCIN-RESISTANT ENTEROCOCCUS OUTBREAK AT A TERTIARY-CARE HOSPITAL IN BANGKOK, THAILAND.

Authors:  Darunee Chotiprasitsakul; Pitak Santanirand; Phantanee Thitichai; Porpon Rotjanapan; Siriorn Watcharananan; Potjaman Siriarayapon; Narong Chaihongsa; Suntariya Sirichot; Maria Chitasombat; Prawat Chantharit; Kumthorn Malathum
Journal:  Southeast Asian J Trop Med Public Health       Date:  2016-05       Impact factor: 0.267

3.  Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile.

Authors:  S Stubbs; M Rupnik; M Gibert; J Brazier; B Duerden; M Popoff
Journal:  FEMS Microbiol Lett       Date:  2000-05-15       Impact factor: 2.742

4.  High Prevalence of Toxigenic and Nontoxigenic Clostridium difficile Strains in Malaysia.

Authors:  Thomas V Riley; Deirdre A Collins; Rina Karunakaran; Maria Abdul Kahar; Ariza Adnan; Siti Asma Hassan; Nadiah Hanim Zainul; F R Mohammed Rustam; Z Abd Wahab; Ramliza Ramli; Yeong Yeh Lee; Hamimah Hassan
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

5.  Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.

Authors:  R Fekety; L V McFarland; C M Surawicz; R N Greenberg; G W Elmer; M E Mulligan
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

6.  Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany.

Authors:  M Arvand; A M Hauri; N H Zaiss; W Witte; G Bettge-Weller
Journal:  Euro Surveill       Date:  2009-11-12

7.  Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR.

Authors:  H Kato; N Kato; K Watanabe; N Iwai; H Nakamura; T Yamamoto; K Suzuki; S M Kim; Y Chong; E B Wasito
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

8.  Identification of toxigenic Clostridium difficile by the polymerase chain reaction.

Authors:  N Kato; C Y Ou; H Kato; S L Bartley; V K Brown; V R Dowell; K Ueno
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

9.  Clinical Characteristics and Treatment Outcomes of Clostridium difficile Infections by PCR Ribotype 017 and 018 Strains.

Authors:  Jieun Kim; Yeonjae Kim; Hyunjoo Pai
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

10.  Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect.

Authors:  Jatapat Hemapanpairoa; Dhitiwat Changpradub; Sudaluck Thunyaharn; Wichai Santimaleeworagun
Journal:  Infect Drug Resist       Date:  2019-07-11       Impact factor: 4.003

View more
  2 in total

1.  Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017.

Authors:  Korakrit Imwattana; Papanin Putsathit; Deirdre A Collins; Teera Leepattarakit; Pattarachai Kiratisin; Thomas V Riley; Daniel R Knight
Journal:  Microb Genom       Date:  2022-03

2.  Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.

Authors:  Hong Yang; Zhihua Ran; Meng Jin; Jia-Ming Qian
Journal:  Gut Liver       Date:  2022-05-25       Impact factor: 4.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.